<p><em><strong>明确承诺：不进行反向股票拆分</strong></em></p>
<p>正如许多股东所知，OSR Holdings 于 2026 年 5 月 11 日向美国证券交易委员会提交了其初步代理声明（Schedule PRE 14A）。鉴于我们纳斯达克最低出价合规截止日期临近，我们认为提供直接且明确的透明度关于我们的战略是重要的。</p>
<p>值得注意的是，PRE 14A 中并未包含授权反向股票拆分的提案。</p>
<p>这是一个经过深思熟虑的决定，反映了我们的坚定信念。</p>
<p><strong>我们不会追求反向股票拆分。</strong></p>
<p>管理层已经评估了这一路径并拒绝了它。我们认为反向拆分不会创造股东价值。这是结构性操作，无法改变商业基本面。我们打算通过有机执行来恢复我们的纳斯达克最低出价合规，而不是通过财务工程。</p>
<p><strong>致力于通过子公司里程碑推动有机复苏</strong></p>
<p>在 2026 年 4 月 29 日，OSR Holdings 与 BCM Europe AG 签署了关于 VXM01 的全球独占许可的最终协议，代表着高达 8.15 亿美元的潜在里程碑付款，并标志着我们肿瘤学平台的一个重大里程碑。</p>
<p>与此同时，Woori IO 通过与三星电子的合作，继续推进其非侵入性血糖监测平台，同时在与国药集团的保密协议下推进讨论。</p>
<p>这些都是建立真正、持久的股东价值的发展。我们打算继续实现这些目标。</p>
<p><strong>我们的立场明确</strong></p>
<p>管理层完全专注于通过运营执行和战略里程碑交付来恢复股东价值。我们相信这是我们股东、我们的业务以及 OSR Holdings 作为一家上市公司的长期信誉的正确前进道路。</p>
<p>不会进行反向拆分。我们相信市场将反映我们正在建立的基本价值。</p>
<p><strong>通过执行承诺纳斯达克合规</strong></p>
<p>管理层仍然完全致力于通过持续交付有意义的公司里程碑和与投资社区的有序互动来恢复与纳斯达克最低出价要求的合规，而不是通过不改善我们商业基本面的结构性行动。</p>
<p>虽然无法保证时间或结果，但我们仍然与我们的顾问和纳斯达克保持充分沟通，努力在我们自己的条件下恢复合规。</p>
<p>我们感谢股东的持续支持，并对 OSR Holdings 未来的长期机会充满信心。</p>
<p>诚挚的，</p>
<p>Kuk Hyoun &#34;Peter&#34; Hwang</p>
<p>首席执行官</p>
<p>OSR Holdings, Inc.</p>
<p><strong>关于 OSR Holdings, Inc.</strong></p>
<p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家全球医疗保健控股公司，致力于推动健康和保健领域的生物医学创新。通过其子公司，OSR Holdings 从事免疫肿瘤学、再生生物学和医疗设备技术，以改善全球健康结果。了解更多信息，请访问 www.OSR-Holdings.com。</p>
<p><strong>投资者联系</strong></p>
<p>OSR Holdings, Inc.</p>
<p>投资者关系</p>
<p>ir@osr-holdings.com</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明，包括关于纳斯达克合规、战略交易、商业化举措和未来业务发展的声明。前瞻性声明基于当前的期望和假设，并受到可能导致实际结果显著不同的风险和不确定性的影响。读者被警告不要对这些前瞻性声明过度依赖。OSR Holdings 没有义务更新这些声明，除非法律要求。</p>
<p><strong>来源：</strong> OSR Holdings, Inc.</p>
<p>查看原始新闻稿，请访问 ACCESS Newswire</p>
<p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NjEyMw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NjEyMw"/></p>

OSRH

<p>OSR Holdings 的首席执行官 Kuk Hyoun "Peter" Hwang 宣布承诺不进行反向股票拆分，强调这并不会创造股东价值。该公司旨在通过运营执行和战略里程碑恢复纳斯达克合规性，包括与 BCM Europe AG 达成的价值高达 8.15 亿美元的重要许可协议。OSR Holdings 专注于通过其子公司提供真正的价值，并与股东保持透明。首席执行官向利益相关者保证公司的长期潜力和对有机增长的承诺</p>

<p><em><strong>A Clear Commitment: No Reverse Stock Split</strong></em></p>
<div class="lb-trans"><p><em><strong>明确承诺：不进行反向股票拆分</strong></em></p>
</div><p>As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A with the U.S. Securities and Exchange Commission on May 11, 2026. Given the proximity of our Nasdaq minimum bid compliance deadline, we believe it is important to provide direct and unambiguous transparency regarding our strategy.</p>
<div class="lb-trans"><p>正如许多股东所知，OSR Holdings 于 2026 年 5 月 11 日向美国证券交易委员会提交了其初步代理声明（Schedule PRE 14A）。鉴于我们纳斯达克最低出价合规截止日期临近，我们认为提供直接且明确的透明度关于我们的战略是重要的。</p>
</div><p>Notably, the PRE 14A did not include a proposal authorizing a reverse stock split.</p>
<div class="lb-trans"><p>值得注意的是，PRE 14A 中并未包含授权反向股票拆分的提案。</p>
</div><p>This was a deliberate decision, and it reflects our firm conviction.</p>
<div class="lb-trans"><p>这是一个经过深思熟虑的决定，反映了我们的坚定信念。</p>
</div><p><strong>We will not pursue a reverse stock split.</strong></p>
<div class="lb-trans"><p><strong>我们不会追求反向股票拆分。</strong></p>
</div><p>Management has evaluated this path and rejected it. We believe reverse splits do not create shareholder value. They are structural maneuvers that leave business fundamentals unchanged. We intend to earn our Nasdaq minimum bid compliance back through organic execution, not financial engineering.</p>
<div class="lb-trans"><p>管理层已经评估了这一路径并拒绝了它。我们认为反向拆分不会创造股东价值。这是结构性操作，无法改变商业基本面。我们打算通过有机执行来恢复我们的纳斯达克最低出价合规，而不是通过财务工程。</p>
</div><p><strong>Committed to Organic Recovery Driven by Subsidiary Milestones</strong></p>
<div class="lb-trans"><p><strong>致力于通过子公司里程碑推动有机复苏</strong></p>
</div><p>On April 29, 2026, OSR Holdings executed definitive agreements with BCM Europe AG for the global exclusive license of VXM01, representing up to $815 million in potential milestone payments and marking a major milestone for our oncology platform.</p>
<div class="lb-trans"><p>在 2026 年 4 月 29 日，OSR Holdings 与 BCM Europe AG 签署了关于 VXM01 的全球独占许可的最终协议，代表着高达 8.15 亿美元的潜在里程碑付款，并标志着我们肿瘤学平台的一个重大里程碑。</p>
</div><p>In parallel, Woori IO continues to advance its non-invasive glucose monitoring platform through its collaboration with Samsung Electronics, while also progressing discussions under NDA with Sinopharm.</p>
<div class="lb-trans"><p>与此同时，Woori IO 通过与三星电子的合作，继续推进其非侵入性血糖监测平台，同时在与国药集团的保密协议下推进讨论。</p>
</div><p>These are the kinds of developments that build real, durable shareholder value. We intend to continue delivering on them.</p>
<div class="lb-trans"><p>这些都是建立真正、持久的股东价值的发展。我们打算继续实现这些目标。</p>
</div><p><strong>Our Position Is Clear</strong></p>
<div class="lb-trans"><p><strong>我们的立场明确</strong></p>
</div><p>Management is focused entirely on restoring shareholder value through operational execution and strategic milestone delivery. We believe this is the right path forward for our shareholders, for our business, and for the long-term credibility of OSR Holdings as a public company.</p>
<div class="lb-trans"><p>管理层完全专注于通过运营执行和战略里程碑交付来恢复股东价值。我们相信这是我们股东、我们的业务以及 OSR Holdings 作为一家上市公司的长期信誉的正确前进道路。</p>
</div><p>There will be no reverse split. We believe the market will come to reflect the fundamental value we are building.</p>
<div class="lb-trans"><p>不会进行反向拆分。我们相信市场将反映我们正在建立的基本价值。</p>
</div><p><strong>Commitment to Nasdaq Compliance Through Execution</strong></p>
<div class="lb-trans"><p><strong>通过执行承诺纳斯达克合规</strong></p>
</div><p>Management remains fully committed to restoring compliance with Nasdaq's minimum bid requirement through the continued delivery of meaningful corporate milestones and disciplined engagement with the investment community - not through structural actions that do not improve our business fundamentals.</p>
<div class="lb-trans"><p>管理层仍然完全致力于通过持续交付有意义的公司里程碑和与投资社区的有序互动来恢复与纳斯达克最低出价要求的合规，而不是通过不改善我们商业基本面的结构性行动。</p>
</div><p>While there can be no assurance regarding timing or outcomes, we remain fully engaged with our advisors and Nasdaq as we work toward restoring compliance on our own terms.</p>
<div class="lb-trans"><p>虽然无法保证时间或结果，但我们仍然与我们的顾问和纳斯达克保持充分沟通，努力在我们自己的条件下恢复合规。</p>
</div><p>We appreciate the continued support of our shareholders and remain confident in the long-term opportunities ahead for OSR Holdings.</p>
<div class="lb-trans"><p>我们感谢股东的持续支持，并对 OSR Holdings 未来的长期机会充满信心。</p>
</div><p>Sincerely,</p>
<div class="lb-trans"><p>诚挚的，</p>
</div><p>Kuk Hyoun &#34;Peter&#34; Hwang</p>
<div class="lb-trans"><p>Kuk Hyoun &#34;Peter&#34; Hwang</p>
</div><p>Chief Executive Officer</p>
<div class="lb-trans"><p>首席执行官</p>
</div><p>OSR Holdings, Inc.</p>
<div class="lb-trans"><p>OSR Holdings, Inc.</p>
</div><p><strong>About OSR Holdings, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 OSR Holdings, Inc.</strong></p>
</div><p>OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.</p>
<div class="lb-trans"><p>OSR Holdings, Inc.（纳斯达克：OSRH）是一家全球医疗保健控股公司，致力于推动健康和保健领域的生物医学创新。通过其子公司，OSR Holdings 从事免疫肿瘤学、再生生物学和医疗设备技术，以改善全球健康结果。了解更多信息，请访问 www.OSR-Holdings.com。</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>OSR Holdings, Inc.</p>
<div class="lb-trans"><p>OSR Holdings, Inc.</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>ir@osr-holdings.com</p>
<div class="lb-trans"><p>ir@osr-holdings.com</p>
</div><p><strong>Forward Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.</p>
<div class="lb-trans"><p>本新闻稿包含 1995 年《私人证券诉讼改革法案》意义上的前瞻性声明，包括关于纳斯达克合规、战略交易、商业化举措和未来业务发展的声明。前瞻性声明基于当前的期望和假设，并受到可能导致实际结果显著不同的风险和不确定性的影响。读者被警告不要对这些前瞻性声明过度依赖。OSR Holdings 没有义务更新这些声明，除非法律要求。</p>
</div><p><strong>SOURCE:</strong> OSR Holdings, Inc.</p>
<div class="lb-trans"><p><strong>来源：</strong> OSR Holdings, Inc.</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看原始新闻稿，请访问 ACCESS Newswire</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://app.accessnewswire.com/img.ashx/query-aWQ9MTE2NjEyMw" alt="" original-src="https://app.accessnewswire.com/img.ashx?id=1166123"/></p>

CEO 致股东的声明 | OSRH 股票新闻